A Meta-Analysis of Body Composition Changes Associated With Long-term Use of Sodium–Glucose Cotransporter 2 Inhibitors
- 18 December 2025
- journal article
- review article
- Published by Elsevier in Endocrine Practice
- Vol. 32 (4) , 644-650
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca KK
This publication has 29 references indexed in Scilit:
- Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKDJAMA Network Open, 2024
- Empagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine, 2023
- Myopathy Associated With Statins and SGLT2 – A Review of LiteratureCurrent Problems in Cardiology, 2021
- Dapagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine, 2020
- Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 DiabetesHormone and Metabolic Research, 2019
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2019
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trialThe Lancet, 2013
- Inhibition of SGLT2: A Novel Strategy for Treatment of Type 2 Diabetes MellitusClinical Pharmacology & Therapeutics, 2011